Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Kristoffer Sahlholm"'
Autor:
Marta Valle-León, Nil Casajuana-Martin, Claudia Llinas del Torrent, Josep Argerich, Laura Gómez-Acero, Kristoffer Sahlholm, Sergi Ferré, Leonardo Pardo, Francisco Ciruela
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 160, Iss , Pp 114327- (2023)
The striatal dopamine D2 receptor (D2R) is generally accepted to be involved in positive symptoms of schizophrenia and is a main target for clinically used antipsychotics. D2R are highly expressed in the striatum, where they form heteromers with the
Externí odkaz:
https://doaj.org/article/719ba51101504107881ca2cf73a00e28
Autor:
Viktor Burström, Richard Ågren, Nibal Betari, Marta Valle-León, Emilio Garro-Martínez, Francisco Ciruela, Kristoffer Sahlholm
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
The dopamine D4 receptor (D4R) is expressed in the retina, prefrontal cortex, and autonomic nervous system and has been implicated in attention deficit hyperactivity disorder (ADHD), substance use disorders, and erectile dysfunction. D4R has also bee
Externí odkaz:
https://doaj.org/article/e4ac71b4fef348f685b291cd35bd0afc
Autor:
Richard Ågren, Niels Geerdink, Han G. Brunner, Martin Paucar, Erik-Jan Kamsteeg, Kristoffer Sahlholm
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 13, p 10924 (2023)
A five-year-old girl presented with headache attacks, clumsiness, and a history of transient gait disturbances. She and her father, mother, twin sister, and brother underwent neurological evaluation, neuroimaging, and exome sequencing covering 357 ge
Externí odkaz:
https://doaj.org/article/447028757d904137b1786085202f81c5
Autor:
Nibal Betari, Kristoffer Sahlholm, Xavier Morató, Héctor Godoy-Marín, Olga Jáuregui, Knut Teigen, Francisco Ciruela, Jan Haavik
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Serotonin (5-HT) is a hormone and neurotransmitter that modulates neural activity as well as a wide range of other physiological processes including cardiovascular function, bowel motility, and platelet aggregation. 5-HT synthesis is catalyzed by try
Externí odkaz:
https://doaj.org/article/441f33ddf4ad4ea2ae91b5c0606f75b8
Autor:
Richard Ågren, Kristoffer Sahlholm
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
In recent years, transmembrane voltage has been found to modify agonist potencies at several G protein-coupled receptors (GPCRs). Whereas the voltage sensitivities of the Gαi/o-coupled dopamine D2-like receptors (D2R, D3R, D4R) have previously been
Externí odkaz:
https://doaj.org/article/2eb1500bb6bc48329ef59973bfb2836a
Autor:
Richard Ågren, Kristoffer Sahlholm
Publikováno v:
Biomedicines, Vol 10, Iss 1, p 22 (2021)
SB269,652 has been described as the first negative allosteric modulator (NAM) of the dopamine D2 receptor (D2R), however, the binding mode and allosteric mechanism of action of this ligand remain incompletely understood. SB269,652 comprises an orthos
Externí odkaz:
https://doaj.org/article/27a6bd12e74b4978bf80ab239367e4c3
Autor:
Hugo Zeberg, Kristoffer Sahlholm
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-3 (2018)
Externí odkaz:
https://doaj.org/article/b9d3925fcb3c48148d2f0533db951498
Autor:
Chia-Ju Hsieh, Aladdin Riad, Ji Youn Lee, Kristoffer Sahlholm, Kuiying Xu, Robert R. Luedtke, Robert H. Mach
Publikováno v:
Biomolecules, Vol 11, Iss 4, p 529 (2021)
[18F]Fallypride and [18F]Fluortriopride (FTP) are two different PET radiotracers that bind with sub-nanomolar affinity to the dopamine D3 receptor (D3R). In spite of their similar D3 affinities, the two PET ligands display very different properties f
Externí odkaz:
https://doaj.org/article/2e5b88a837b14c0093266e4b72355756
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 8, p 4078 (2021)
The forward (kon) and reverse (koff) rate constants of drug–target interactions have important implications for therapeutic efficacy. Hence, time-resolved assays capable of measuring these binding rate constants may be informative to drug discovery
Externí odkaz:
https://doaj.org/article/37d32818b1b14066a0f3414b4ec6cf8a
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Pridopidine is in clinical trials for Huntington's disease treatment. Originally developed as a dopamine D2 receptor (D2R) ligand, pridopidine displays about 100-fold higher affinity for the sigma-1 receptor (sigma-1R). Interestingly, pridopidine slo
Externí odkaz:
https://doaj.org/article/f4f1e74e03a74135872feee1cd020e42